Cessation of Mr. Pramod Gokhale as SMP and Re-appointment of Mr. Satish Kumar Sharma as Whole Time Director and Re-appointment of Cost Auditor of the Company
MANKIND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Mankind Pharma's Board approved strong Q4 and FY2026 results with standalone revenue of ₹10,421 crore and net profit of ₹713.61 crore. Operating margin improved to 29% and net profit margin to 20%. The Board noted the resignation of Mr. Pramod Gokhale as Global CIO and Senior Management Personnel effective May 31, 2026. Mr. Satish Kumar Sharma was re-appointed as Whole-Time Director for another 5-year term from September 23, 2026, subject to shareholder approval. Cost auditors M/s. M. K. Kulshrestha & Associates were re-appointed for FY2026-27. The company also approved investing up to ₹500 crore in its wholly-owned subsidiary Mankind Medicare. Notably, the Executive Chairman, Vice Chairman & MD, and CEO voluntarily waived their commission for FY2025-26 to strengthen cash position for business expansion.
The strong financial performance with margin improvements is positive. The KMP resignation is a minor governance event. The voluntary commission waiver by top executives signals alignment with shareholders and focus on cash conservation for growth.